Back to top

Immunomedics, Inc. (IMMU)

(Delayed Data from NSDQ)

$14.74 USD


-0.16 (-1.07%)

Updated May 3, 2019 04:00 PM ET

After-Market: $14.75 (%) 5:22 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
5Strong Sell1.87%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank


Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.

Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev

Seagen (SGEN) and partner Astellas Pharma post favorable top-line results from the second cohort of the phase II EV-201 study on Padcev to treat advanced or metastatic urothelial cancer. Stock rises.

Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma

Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.

Axovant's Gene Therapy Gets Rare Pediatric Disease Status

The FDA bestows a Rare Pediatric Disease status on Axovant's (AXGT) gene therapy candidate AXO-AAV-GM1, which is being developed for the treatment of GM1 gangliosidosis. Stock appreciates.

Kinjel Shah headshot

Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia

After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.

Immunomedics Releases Trodelvy Data From Cancer Studies

Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.

Sweta Killa headshot

Healthcare ETFs, Stocks That Gained Double Digits Last Week

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day

Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day

Gilead's Oncology Drug Gets Breakthrough Therapy Designation

Gilead's (GILD) magrolimab obtains Breakthrough Therapy designation in the United States for the treatment of newly-diagnosed myelodysplastic syndrome (MDS).

Sweta Killa headshot

M&A ETFs Sizzling on Recent Deal Activities

After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.

Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?

Investors need to pay close attention to Immunomedics (IMMU) stock based on the movements in the options market lately.

Sweta Killa headshot

Biotech ETFs Soars on Gilead-Immunomedics Deal

The acquisition will expand Gilead's portfolio of treatments for various types of cancer.

Stock Market News for Sep 15, 2020

U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

Sweta Killa headshot

ETFs in Focus on Tug of War Between Bulls and Bears

Both bull and bear ETFs are showing immense potential as abrupt changes in sentiments have raised the appeal for these products.

M&A Activities Intensify in Pharma Industry

M&A Activities Intensify in Pharma Industry.

Mark Vickery headshot

No Econ Data, but Big Biopharma News

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Gilead to Buy Oncology Company Immunomedics for $21 Billion

Gilead (GILD) looks to fortify its oncology portfolio with the acquisition of Immunomedics and the addition of Trodelvy to its portfolio.

Immunomedics to be Acquired by Gilead for About 21 Billion

Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.

Why Is Immunomedics (IMMU) Down 6.7% Since Last Earnings Report?

Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immunomedics (IMMU) Reports Q2 Loss, Lags Revenue Estimates

Immunomedics (IMMU) delivered earnings and revenue surprises of 11.76% and -19.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day

Advanced Micro Devices, Under Armour, Immunomedics, GenMark and Co-Diagnostics highlighted as Zacks Bull and Bear of the Day

3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD

Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.

Immunomedics Extends Deal With Roche for Two New Studies

Immunomedics (IMMU) extends agreement with Roche to evaluate the combination of Trodelvy and Tecentriq in patients with mUC and mNSCLC.

Amgen (AMGN) Invests Further in China-Based Oncology Partner

Amgen (AMGN) announces additional investment of approximately $421 million in BeiGene. The companies have a collaboration for oncology products signed in 2019.